Day: July 27, 2020

ALPHARETTA, Ga., July 27, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple posters and oral presentations on Clearside’s pipeline and its proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) were delivered at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting.“Clearside continues to stay top-of-mind with the ophthalmic and retina communities as our clinical development pipeline and suprachoroidal delivery system are featured at prominent medical meetings,” said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer. “This year, ASRS held a successful annual...

Company reports EPS of $0.65, Economic EPS of $2.74 in second quarter of 2020Net Income (controlling interest) of $31 million, Economic Net Income of $130 million  Issued $350 million 10-year senior bond, extending duration and enhancing financial flexibility  Announced partnership with Inclusive Capital Partners, first Affiliate wholly focused on responsible capitalism  Repurchased $50 million in common stock  WEST PALM BEACH, Fla., July 27, 2020 (GLOBE NEWSWIRE) — Affiliated Managers Group, Inc. (NYSE: AMG) today reported its financial and operating results for the second quarter and six months ended June 30, 2020.Jay C. Horgen, President and Chief Executive Officer of AMG, said:“In a period of significant ongoing uncertainty, AMG reported Economic earnings per share of $2.74 for the second quarter. Net client cash flows were...

LAS VEGAS and VANCOUVER, British Columbia, July 27, 2020 (GLOBE NEWSWIRE) — TAAT LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTC: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “Taat”) announces that shortly after entering into an agreement with its first distribution partner for Beyond Tobacco™ cigarettes, it has added new distributorship with California-based West Coast Vape Supply, Inc. (“WCVS”) with a one-year comprehensive distribution agreement that took effect on July 24, 2020. WCVS has a flagship retail location in Huntington Beach, CA, in addition to an e-commerce platform with more than 300,000 customers, and a distribution network that ultimately reaches more than 20,000 retail stores across the United States. In anticipation of the planned Q4 2020 launch of Beyond Tobacco™ cigarettes, the Company has prioritized the procurement...

CALGARY, Alberta, July 27, 2020 (GLOBE NEWSWIRE) — STEP Energy Services Ltd. (“STEP”) intends to release its 2020 second quarter results on Thursday, August 13th, 2020 after markets close.Financial Statements and Management’s Discussion and Analysis will be posted to STEP’s website and SEDAR immediately after the press release is disseminated.ABOUT STEPSTEP is an oilfield service company founded in 2011 that provides fully integrated coiled tubing and fracturing solutions. STEP’s combination of modern, fit-for-purpose fracturing and coiled tubing equipment has differentiated it in plays where wells are deeper, have longer laterals, and higher pressure.Initially operating as a specialized, deep capacity coiled tubing provider, STEP’s service offering expanded to include fully integrated coiled tubing and fracturing solutions....

NEW YORK & SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a clinical collaboration agreement with Eli Lilly and Company (NYSE: LLY, “Lilly”) in which Zentalis will evaluate the combination of ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, and Verzenio® (abemaciclib), Lilly’s CDK4 and 6 inhibitor, in patients with ER+/HER2- advanced breast cancer.“This is a new, separate study, that allows us to evaluate the potential of our compound in combination with Lilly’s CDK4 and 6 inhibitor,” commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis Pharmaceuticals....

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATESSANTA CRUZ, Calif. and TORONTO, July 27, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions Corp. (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29) (the “Company” or “NexTech”), is pleased to announce that its offering, previously announced on July 23, 2020 (the “Offering”), will be for an offering size of up to $15,000,000. The Offering will be conducted on an agency basis for the issuance of up to 2,307,692 units of the Company (the “Units”) at a price of $6.50 per Unit. The Offering is being led by Mackie Research Capital Corporation as sole agent and sole bookrunner (the “Agent”).Each Unit shall be comprised of one common share in the capital of the Company (each a...

WATERTOWN, Mass., July 27, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of data supporting YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye. The data were presented in two oral sessions at the American Society of Retina Specialists (ASRS) Virtual Annual Meeting held July 24 – 26, 2020.“These supportive results continue to build on the strong product profile of YUTIQ, which provides sustained and long-lasting anti-inflammatory activity for up to 36 months for this difficult to treat ocular disease,” said Nancy Lurker, President and Chief Executive Officer of EyePoint...

AGOURA HILLS, Calif., July 27, 2020 (GLOBE NEWSWIRE) — Mateon Therapeutics (OTC.QB: MATN) announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its EdgePoint AI, Inc. (“EdgePoint”, a Delaware Corporation and a division of Mateon). JH Darbie & Co., Inc. is acting as the exclusive placement agent for the Offering. The Offering consists of a minimum of 40 units on a best effort all or none basis and a maximum of up to 100 units on a best effort basis at a price per unit of $50,000 (the “Units”).  This initial closing is for the sale of 40 Units.  Each Unit allows the Unit holder to purchase 25,000 shares of the Common Stock of EdgePoint (Mateon’s artificial intelligence (“AI”) division) and one note issued by Mateon (the “Note”). Each Note is convertible into up to 25,000 shares...

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) will be presented in a poster at the American Academy of Neurology’s first-ever Sports Concussion Conference. The research was sponsored by Trigemina, Inc. and in June Tonix acquired the assets of Trigemina including certain rights to the data described on the poster.  Dr. Shashidhar Kori was formerly chief medical officer of Trigemina.  Dr. David Yeomans and Dr. Michael Klukinov are on the faculty of Stanford University.  Dr. Kori and Dr. Yeomans are currently consultants to Tonix. The virtual meeting is being held July 31 and August 1, 2020.Details of the poster presentation:Title: ...

紐約洲水牛城, July 27, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX) 是一家致力於研究、開發和商業化治療癌症和相關疾病新療法的的全球生物製藥公司，其今天宣佈將在 2020 年 8 月 6 日（星期四）市場開放前，發佈 2020 年第二季度財務業績，且會於東岸時間上午 8 時提供現場電話會議和聲音網絡講解財務報告及提供業務近況。若要參與本次會議，請在電話會議前十五分鐘致電 877-407-0784 （本地）或 201-689-8560 （國際），並提述會議驗証碼 13706637。現場電話會議和聲音網絡重播都可以在公司網站的投資者關係頁面上取得，網址為：http://ir.athenex.com/。關於 Athenex, Inc.創於 2003 年，Athenex, Inc. 是一家臨床階段的國際生物製藥公司，並致力成為研究、開發及將下一代癌症治療藥物商業化的領導者。Athenex 下設三個平台，分別為腫瘤創新平台、商業平台和全球供應鏈平台。公司現有的臨床產品系列源自四個不同平台的科技：(1) 以 p-糖蛋白抑制劑為基礎的 Orascovery；(2) Src 酶抑制劑；(3) 受體工程化 T 細胞 (TCR-T) 及 (4) 精氨酸消除療法。Athenex 的員工遍佈全球，致力透過開發更有效及耐受的治療來改善癌症病人的生活。Athenex 在紐約州的水牛城和克拉倫斯、德州的休斯頓、伊利諾伊州的芝加哥、香港、台灣的台北、中國的重慶、英國的曼徹斯特、危地馬拉的危地馬拉市及阿根廷的布宜諾斯艾利斯等多個地方，均設有辦事處。如欲了解更多資訊，請瀏覽 www.athenex.com。聯絡人Athenex, Inc.：Daniel Lang，執行董事企業發展及企業傳訊電郵：danlang@athenex.comJacqueline Li公司發展與投資者關係電郵：jacquelineli@athenex.com投資者關係：Tim...